All Releases
 |
Theravance Announces New Employment Inducement Awards
Jul 1, 2009
|
8.9 KB |
|
| |
SOUTH SAN FRANCISCO, CA/July 1, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to...
|
|
Theravance Announces New Employment Inducement Awards
Jun 4, 2009
|
8.9 KB |
|
| |
SOUTH SAN FRANCISCO, CA/June 4, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to two new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to fac...
|
|
Theravance to Present at Investor Conferences in June 2009
Jun 2, 2009
|
11.4 KB |
|
| |
SOUTH SAN FRANCISCO, CA/June 2, 2009 -- Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Senior Vice President and Chief Financial Officer, is scheduled to present at the following investor conferences in June 2009:
Goldman Sachs 30th Annual Global Healthcare Conference
Grand Hyatt, ...
|
|
Theravance Announces New Employment Inducement Awards
May 4, 2009
|
8.9 KB |
|
| |
SOUTH SAN FRANCISCO, CA/May 4, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopt...
|
|
Theravance to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
Apr 30, 2009
|
10.6 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 30, 2009 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009, at 10:00 a.m. EDT. The conference will be held from March 12-14, 2009 at T...
|
|
FDA Accepts for Review Theravance's Complete Response Submission for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Apr 24, 2009
|
12.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 24, 2009 - Theravance, Inc. (NASDAQ: THRX) announced today that the U.S. Food and Drug Administration (FDA) accepted as complete for review Theravance's response to the February 2009 Complete Response letter, which outlined requirements for approval of telavancin for the treatment of complicated skin and skin structure...
|
|
Theravance Reports First Quarter 2009 Financial Results
Apr 22, 2009
|
16.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 22, 2009 - Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended March 31, 2009. Net loss for the first quarter of 2009 was $19.2 million compared with $29.8 million for the same period of 2008, a decrease of $10.6 million. Net loss per share was $0.31 for the first quarte...
|
|
Theravance to Webcast 2009 Annual Meeting of Stockholders on April 24, 2009
Apr 16, 2009
|
10.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 16, 2009 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2009 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Friday, April 24, 2009.
An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight Time. To participate in the live call b...
|
|
Theravance to Report First Quarter 2009 Financial Results on April 22, 2009
Apr 8, 2009
|
9.3 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 8, 2009 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended March 31, 2009 after market close on Wednesday, April 22, 2009.
An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call by telephone,...
|
|
Theravance Announces FDA Acceptance of Telavancin NDA for the Treatment of Hospital-Acquired Pneumonia
Apr 6, 2009
|
13.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 6, 2009 - Theravance, Inc. (NASDAQ: THRX) announced today that the U.S. Food & Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic, for the treatment of nosocomial pneumonia (also known as hospital-acqui...
|
|
Theravance Announces New Employment Inducement Awards
Apr 1, 2009
|
8.6 KB |
|
| |
SOUTH SAN FRANCISCO, CA/April 1, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to four new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to f...
|
|
Theravance to Present at the Cowen and Company 29th Annual Health Care Conference
Mar 3, 2009
|
10.1 KB |
|
| |
SOUTH SAN FRANCISCO, CA/March 3, 2009 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009, at 10:15 a.m. EDT. The conference will be held from March 16-19, 2009 at the Boston ...
|
|
Theravance Announces New Employment Inducement Award
Mar 2, 2009
|
8.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA/March 2, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that an equity award was made to one new employee. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity award was granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to fa...
|
|
Theravance Receives Complete Response Letter on the Telavancin New Drug Application for the Treatment of cSSSI
Feb 26, 2009
|
14.3 KB |
|
| |
SOUTH SAN FRANCISCO, CA/February 26, 2009 - Theravance, Inc. (NASDAQ: THRX) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) outlining requirements for approval of telavancin for the treatment of complicated skin and skin structure infections (cSSSI). Telavancin is a novel, bacte...
|
|
Theravance Reports Fourth Quarter and Full Year 2008 Results
Feb 12, 2009
|
91.6 KB |
|
| |
Theravance Reports Fourth Quarter and Full Year 2008 ResultsTheravance Reports Fourth Quarter and Full Year 2008 ResultsSOUTH SAN FRANCISCO, CA/February 12, 2009 - Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the fourth quarter ...
|
|
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
Feb 4, 2009
|
24.6 KB |
|
| |
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three, separate phase 2b studies assessing efficacy and safety of GSK's inhaled corticosteroid (ICS) fluticasone furoate (FF or GW685698) across a range of eight doses (25 - 800 mcg) in over 1,800 patients with mild, moderate and severe asthma. Once-d...
|
|
Theravance Announces New Employment Inducement Awards
Feb 2, 2009
|
8.9 KB |
|
| |
SOUTH SAN FRANCISCO, CA/February 2, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to four new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopte...
|
|
Theravance to Report Fourth Quarter and Full Year 2008 Financial Results on February 12, 2009
Jan 29, 2009
|
9.4 KB |
|
| |
SOUTH SAN FRANCISCO, CA/January 29, 2009 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2008 after market close on Thursday, February 12, 2009.
An accompanying conference call will be held at 5:00 p.m. Eastern Standard Time. To participate...
|
|
Theravance Submits U.S. NDA for Telavancin for the Treatment of Hospital-Acquired Pneumonia
Jan 26, 2009
|
13.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA/January 26, 2009 - Theravance, Inc. (NASDAQ: THRX) announced today that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic, for the proposed indication to treat nosocomial pneumonia (also kn...
|
|
Theravance Announces New Employment Inducement Award
Jan 5, 2009
|
8.9 KB |
|
| |
SOUTH SAN FRANCISCO, CA/January 5, 2009 -- Theravance, Inc. (NASDAQ: THRX) today reported that an equity award was made to one new employee. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity award was granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to ...
|
|
|
